Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial
May 23, 2017
PDF 282.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma
May 19, 2017
PDF 284.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress
May 18, 2017
PDF 284.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
May 17, 2017
PDF 285.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results
May 5, 2017
PDF 291.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update
May 3, 2017
PDF 278.8 KB Add to Briefcase
View Summary TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting
Apr 28, 2017
PDF 285.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
Apr 24, 2017
PDF 283.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
Apr 20, 2017
PDF 286.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
Apr 4, 2017
PDF 284.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting
Mar 20, 2017
PDF 283.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference
Mar 17, 2017
PDF 278.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference
Mar 13, 2017
PDF 278.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update
Mar 10, 2017
PDF 296.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results and Business Update
Mar 9, 2017
PDF 278.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock
Mar 9, 2017
PDF 281.9 KB Add to Briefcase
View Summary TG Therapeutics Announces Proposed Public Offering of Common Stock
Mar 8, 2017
PDF 282.0 KB Add to Briefcase
View Summary TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL)
Mar 6, 2017
PDF 329.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
Mar 3, 2017
PDF 284.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology
Feb 21, 2017
PDF 284.1 KB Add to Briefcase
Showing 1-20 of 184 Page: 1 2 3 4 5 ... 10  Next 20
Add to Briefcase = add release to Briefcase